Vident Advisory’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$771K Buy
30,779
+622
+2% +$15.8K 0.01% 1121
2026
Q2
$765K Sell
30,157
-3,956
-12% -$93.5K 0.01% 1129
2026
Q1
$771K Buy
34,113
+10,542
+45% +$234K 0.01% 996
2025
Q4
$610K Buy
23,571
+3,075
+15% +$73.1K 0.01% 1053
2025
Q3
$528K Buy
20,496
+2,255
+12% +$55.4K 0.01% 1180
2025
Q2
$436K Sell
18,241
-2,078
-10% -$52.4K ﹤0.01% 1142
2025
Q1
$505K Sell
20,319
-9,035
-31% -$216K 0.01% 1027
2024
Q4
$553K Sell
29,354
-1,493
-5% -$26.2K 0.01% 889
2024
Q3
$464K Buy
+30,847
New +$527K 0.01% 963

Other funds holding PCRX

Vident Advisory's PCRX Position: Q3 2026 in Review

Vident Advisory increased its Pacira BioSciences (PCRX) stake by 2.1% in Q3 2026, buying an estimated $15.8K and bringing the position to 30,779 shares worth $771K. The position accounts for 0.01% of the portfolio, ranked #1121.

Vident Advisory first reported a position in PCRX in Q3 2024 and has held it in 9 quarters since. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Vident Advisory held 30,779 shares of Pacira BioSciences worth $771K as of Q3 2026.
  • Vident Advisory bought 622 Pacira BioSciences shares in Q3 2026, an estimated $15.8K.
  • Pacira BioSciences made up 0.01% of Vident Advisory's portfolio in Q3 2026, its #1121 holding.
  • Vident Advisory first reported a position in Pacira BioSciences in Q3 2024 and has held it in 9 quarters since.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Vident Advisory's 13F filing for Q3 2026, filed 16 Nov 2026.